Pure Global AI
NCT06150781Recruiting

Aimovig Pregnancy Exposure Registry

GENESIS: AIMOVIG® Pregnancy Exposure Registry
AmgenClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Migraine
Drug/Device/Intervention
erenumab-aooe
Study type
Observational
Intervention type
drug
Sponsor & location
Primary sponsor
Amgen
Location
Durham, United States of America
Timeline & enrollment
Phase
N/A
Start date
Jan 27, 2021
End date
Oct 28, 2027
Enrollment
2842 participants
Primary outcome

Number of Infants Experiencing Major Congenital Malformations

Summary

The primary objective of this study is to estimate the proportion of major congenital
 malformations in infants of women with migraine exposed to erenumab-aooe during pregnancy
 compared to infants of women with migraine unexposed to erenumeb-aooe.

ICD-10 classifications
MigraineOther migraineMigraine, unspecifiedComplicated migraineHeadache
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06150781
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06150781 through Pure Global AI's free database. This phase not specified trial is sponsored by Amgen and is currently Recruiting. The study focuses on Migraine. Target enrollment is 2842 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.